Pfizer at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

Pfizer brings 1 presentation to ENA 2026 in Barcelona, and exhibits at Booth 26. Its program centres on PF-08098488, a CEACAM5-targeting MMAE antibody-drug conjugate. The conjugate uses optimized engineered-cysteine sites designed to improve its therapeutic index and shows potent antitumor activity in preclinical models.

Organization	ENA 2026 Attendance
Pfizer New York, New York
pfizer.com Large pharmaExhibitor Global pharmaceutical company whose oncology portfolio includes antibody-drug conjugates gained with Seagen.	Booth Exhibiting at Booth 26 Wed, Nov 1812–7pmThu, Nov 199am–5:30pmFri, Nov 209am–3pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates PF‑08098488, A Novel CEACAM5-Targeting MMAE ADC with Optimized Engineered-Cysteine Sites Designed to Enhance Therapeutic Index, Demonstrates Potent Antitumor Activity in Preclinical Models ADCs & radioligands

Organization

ENA 2026 Attendance

Pfizer

New York, New York

pfizer.com

Large pharmaExhibitor

Global pharmaceutical company whose oncology portfolio includes antibody-drug conjugates gained with Seagen.

Booth

Exhibiting at Booth 26

Wed, Nov 1812–7pmThu, Nov 199am–5:30pmFri, Nov 209am–3pm

Poster

Wed Nov 18
12–1:30pm
3:50–4:15pm
5:45–7pm